CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Chemokine receptors, particularly CXCR4, are emerging therapeutic targets in multiple myeloma (MM).
• CXCR4 expression on myeloma cells is known to be dynamic and influenced by various factors.
• Understanding these dynamics is crucial for optimizing CXCR4-targeted treatment strategies.

Purpose of the Study:

• To investigate the in vitro impact of common anti-myeloma agents on CXCR4 expression in multiple myeloma cells.
• To determine how different drugs, doses, and treatment durations affect CXCR4 levels.
• To assess the implications of these expression changes on the efficacy of CXCR4-based therapies.

Main Methods:

• Utilized established human myeloma cell lines and patient-derived CD138+ plasma cells.
• Exposed cells to various antineoplastic drugs, including bortezomib, dexamethasone, and doxorubicin.
• Quantified CXCR4 expression using flow cytometry and direct stochastic optical reconstruction microscopy (dSTORM).
• Assessed cellular uptake of the PET radiotracer 68Ga-Pentixafor.

Main Results:

• CXCR4 expression exhibited significant variability, dependent on drug substance, dose, and treatment time.
• Bortezomib treatment led to decreased CXCR4 expression.
• Dexamethasone and doxorubicin significantly increased CXCR4 expression.
• Combinations of these drugs further augmented CXCR4 expression.

Conclusions:

• Commonly used anti-myeloma drugs can modulate CXCR4 expression in multiple myeloma cells.
• Pretreatment with certain agents can induce or alter CXCR4 expression levels.
• These drug-induced changes in CXCR4 expression may influence the response to subsequent CXCR4-targeted therapies.